In this murine model of early-stage PBC, treatment with a SR antagonist (Sec 5–27) reduced SR activation and subsequently decreased TGF-β1 expression, biliary senescence, and liver fibrosis (Kennedy et al., 2019). This evidence concerns the gene TGFB1 and Hepatic fibrosis.